Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2

Pharmacology and Therapeutics

Volumn 93, Issue 2-3, 2002, Pages 113-124

  Johnson, Louise N ^a   De Moliner, Erika ^a,b   Brown, Nick R ^a   Song, Haiwei ^a   Barford, David ^c   Endicott, Jane A ^a   Noble, Martin E M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF PADOVA   (Italy)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cancer; CDK2 inhibitors; Kinase associated phosphatase; Kinase phosphatase recognition; Staurosporine; UCN 01

Indexed keywords

7 HYDROXYSTAUROSPORINE; ADENINE; ADENOSINE TRIPHOSPHATE; ALANINE; CYCLIN A; HYDROXYL GROUP; PHOSPHATASE; SERINE; STAUROSPORINE; THREONINE; WATER; CDK2 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ENZYME INHIBITOR; PROTEIN SERINE THREONINE KINASE;

CATALYSIS; CELL CYCLE; CLINICAL TRIAL; CONFERENCE PAPER; DEPHOSPHORYLATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HYDROGEN BOND; MITOSIS; PRIORITY JOURNAL; DRUG EFFECT; ENZYMOLOGY; METABOLISM; MOLECULAR BIOLOGY; NEOPLASM; PHYSIOLOGY; REVIEW; STRUCTURE ACTIVITY RELATION;

CYCLIN-DEPENDENT KINASES; CYCLINS; ENZYME INHIBITORS; HUMAN; MOLECULAR BIOLOGY; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; STAUROSPORINE; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, NON-U.S. GOV'T; CDC2-CDC28 KINASES; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS;

EID: 0035990909     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(02)00181-X     Document Type: Conference Paper

References (45)

1. The crystal structure of cyclin A
2. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases
3. Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity
4. 7-Hydroxystaurosporine causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin induced S-phase arrest in Chinese hamster ovary cells
5. Old and new therapies in chronic lymphocytic leukemia: Now is the time for reassessment of therapeutic goals
6. The 1.7 Å crystal structure of human cell cycle checkpoint kinase Chk1: Implications for Chk1 regulation
7. Dephosphorylation of human cyclin-dependent kinases by protein phosphatase type 2Cα and β2 isoforms
8. Structure-based design of cyclin-dependent kinase inhibitors
9. Crystal structure of cyclin dependent kinase 2
10. Crystal structure of the catalytic domain of the human cell cycle control phosphatase Cdc25A
11. Absolute configuration of staurosporine by X-ray analysis
12. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha 1-acid glycoprotein
13. Analogs of staurosporine: Potential anticancer drugs?
14. The chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
15. Cdi 1, a human G1 and S phase protein phosphatase that associates with Cdk2
16. KAP: A dual specificity phosphatase that interacts with cyclin-dependent kinases
17. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage
18. Programmed cell death and Bc1-2 protection in the absence of a nucleus
19. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex
20. The structural basis for control by phosphorylation
21. UCN-01, 7-hydroxystaurosporine, inhibits kinase activity of cyclin dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line
22. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia
23. Purification, characterisation and kinetic mechanism of cyclinD1-CDK4, a major target for cell regulation
24. Protein kinase inhibition by staurosporine: Details of the molecular interaction determined by X-ray crystallographic analysis of a CDK2-staurosporine complex
25. Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines
26. Reversible inactivation of PTP1B in A431 cells stimulated with epidermal growth factor
27. Different susceptibility of protein kinases to staurosporine inhibition
28. Chemical inhibitors of cyclin dependent kinases
29. Synergistic interactions between UCN-01 and various anti-cancer agents in vitro: Relationship to p53 function
30. Cyclin-dependent kinases: Engines, clocks and microprocessors
31. A new inhibitor of protein kinase C, RK-286C (4′-demethylamino-4′-hydroxystaurosporine)
32. Mechanisms of cyclin dependent regulations: Structures of cdks, their cyclin activators, and cip and INK4 inhibitors
33. Dephosphorylation of Cdk2 Thr160 by the cyclin dependent kinase-interacting phosphatase KAP in the absence of cyclin
34. Structural basis of cyclin dependent kinase activation by phosphorylation
35. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms
36. Preclinical and clinical development of cyclin-dependent kinase modulators
37. Differential inhibition of protein kinase C isoenzymes by UCN-01, a staurosporine analogue
38. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function
39. Anticancer drug targets: Cell cycle and checkpoint control
40. Phospho-protein/protein interactions: The crystal structure of kinase associated phosphatase (KAP) in complex with CDK2
41. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/ or G2 checkpoint abrogation
42. UCN-01, a selective inhibitor of protein kinase C from Streptomyces
43. 2+ dependent protein kinase
44. Apoptosis in 7-hydroxystaurosporine treated T lymphocytes correlates with activation of cyclin dependent kinases 1 and 2
45. UCN-01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53